Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

294.76 -3.49 (-1.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
55 56 Next >
Can You Still Buy the Dow Jones' Best-Performing April Stocks?
Each is benefiting from recent good news, but there's also a theme-based tailwind brewing that could last a while. 
Via The Motley Fool
Love Dividends? These 3 Stocks Are Smart Buys Right Now
With yields of 3.1%, 3.4%, and 14.3%, these stocks are hard to pass up right now. 
Via The Motley Fool
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up... 
Via Talk Markets
ROSEN, A LONGSTANDING LAW FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AMGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Regulatory Compliance
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DraftKings, SVB, Amgen, and Signature and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
1 Dividend Growth Stock to Buy Hand Over Fist
Investing in dividend stocks, particularly those that raise their payouts regularly, can pay off massively in time. 
Via The Motley Fool
ROSEN, A LEADING LAW FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
From The Rosen Law Firm PA
Via GlobeNewswire
7 Very Undervalued Penny Stocks to Buy in April 2023
Undervalued penny stocks present investors who are very bullish on the near-term future with a high-risk, high-reward option. 
Via InvestorPlace
Amgen Inc. (NASDAQ: AMGN) Shareholder Alert: Lawsuit Alleges Misleading Statements
San Diego, CA -- (SBWIRE) -- 04/06/2023 -- An investor, who purchased shares of Amgen Inc. (NASDAQ: AMGN), filed a lawsuit over alleged violations of Federal Securities Laws by Amgen Inc. in connection... 
Via SBWire
Income Investors: These 2 Stocks Have Quadrupled Their Dividend Payouts Over the Past 10 Years
These two stocks have generated massive dividend growth for shareholders in the last decade. 
Via The Motley Fool
Amgen's Debt Overview
Via Benzinga
A Look Into Amgen Inc's Price Over Earnings
Via Benzinga
3 Must-Buy Dow Stocks for Your April Buy List
The range of Dow stocks to choose from is small, but there are plenty of great opportunities for investors to choose from. 
Via InvestorPlace
3 Dow Stocks With Above-Average Dividends Yields to Buy in April
Income-seeking investors are going to love the annual payout raises and yields of 2.9% or better that these legendary dividend payers offer right now. 
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, Signature, and Norfolk Southern and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AMGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Regulatory Compliance
Amgen Options Traders Betting On Stock Rising This Much By April Expiration
Within the next month, Amgen Inc. (NASDAQ: AMGN) is expected to report quarterly earnings at $4 per share on revenue of $6.26 billion, analysts say. 
Via Benzinga
This Blue Chip Dividend Stock Should Return to Form When the Risk Premium Flips
T-bills may be the flavor of the month, but history has shown this top biotech stock is a far better long-term investment. 
Via The Motley Fool
The Government Move That Could Drive Obesity Drugs — And Lilly, Novo Shares
The decision from the WHO could further bolster use of Novo's Saxenda and Wegovy. 
Via Investor's Business Daily
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run
Viking Therapeutics stock might in the midst of a historic run. 
Via The Motley Fool
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AMGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Regulatory Compliance
Viking Therapeutics' Initial VK2735 'Data Resoundingly Beat Expectations,' Analyst Says
Earlier today, Viking Therapeutics Inc (NASDAQ: VKTX) announced the first-in-human single-ascending dose and multiple-ascending dose data of VK2735. 
Via Benzinga
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP 
Via MarketBeat
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Match, DraftKings, SVB, and Amgen and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Amgen Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AMGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Regulatory Compliance
The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win
The company is working on an oral version of its cult-following injection, Ozempic. 
Via Investor's Business Daily
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DraftKings, SVB, Amgen, and Signature and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amgen Inc. (AMGN)
From Glancy Prongay & Murray LLP
Via Business Wire
Nvidia's Artificial Intelligence Market Strategy Impresses Wall Street
Analysts on Wednesday praised Nvidia's approach to artificial intelligence as it moves deeper into software and services. NVDA stock rose. 
Via Investor's Business Daily
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.